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SUMMARY
Treatment with praziquantel (PZQ) has become virtually the sole basis of schistosomiasis control in sub-Saharan Africa
and elsewhere, and the drug is reviewed here in the context of the increasing rate that it is being used for this purpose.
Attention is drawn to our relative lack of knowledge about the mechanisms of action of PZQ at the molecular level, the need
for more work to be done on schistosome isolates that have been collected recently from endemic areas rather than those
maintained in laboratory conditions for long periods, and our reliance for experimental work mainly on Schistosoma
mansoni, little work having been done on S. haematobium. There is no evidence that resistance to PZQ has been induced in
African schistosomes as a result of its large-scale use on that continent to date, but there is also no assurance that PZQ and/
or schistosomes are in any way unique and that resistant organisms will not be selected as a result of widespread drug usage.
The failure of PZQ to produce complete cures in populations given a routine treatment should therefore solicit considerable
concern.With few alternatives to PZQ currently available and/or on the horizon, methods tomonitor drug-susceptibility in
African schistosomes need to be devised and used to help ensure that this drug remains eﬀective for as long a time as
possible.
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INTRODUCTION
The majority of serious schistosome infections are
now found in sub-Saharan Africa (van der Werf
et al. 2003). The ‘Schistosomiasis Control Initiative’
(SCI; http://www.schisto.org), funded by the Bill
and Melinda Gates Foundation, is based on the use
praziquantel (PZQ) to reduce schistosome-induced
morbidity (Fenwick et al. 2003) and is currently ac-
tive in eight African countries. A continuation of this
trend will result in even greater use of PZQ (Fenwick
et al. 2006; Doenhoﬀ, Cioli and Utzinger, 2008).
The desirability of integrating initiatives to control
schistosomiasis using PZQ with other helminth
control programmes has begun to be stressed (Brady,
Hooper and Ottesen, 2006; Fenwick, 2006; Lammie,
Fenwick and Utzinger, 2006; Hotez et al. 2007;
Brooker et al. see in this special issue).With regard to
chemotherapy-based control eﬀorts to tackle mul-
tiple helminth diseases concurrently, the reader is
referred to a manual by the World Health Organiz-
ation (WHO) entitled ‘‘Preventive chemotherapy
in human helminthiasis ’’ (http://whqlibdoc.who.int/
publications/2006/9241547103_eng.pdf).
Factors contributing to the usefulness of PZQ are
its excellent pharmacological properties, a substan-
tial reduction in price (Fenwick et al. 2003; Hagan
et al. 2004) and the realization that schistosome-
induced morbidity has been underestimated (Engels
et al. 2002; King, Dickman and Tisch, 2005; King
andBertino, 2008;KingandDangerﬁeld-Cha, 2008).
PZQ has therefore become not just the drug-of-
choice, but eﬀectively the only treatment for this
disease and it is as a result of the SCI and other in-
itiatives that its use for the treatment of schistoso-
miasis has recently increased markedly (Southgate
et al. 2005).
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PRAZIQUANTEL
PZQ [2-(cyclohexylcarbonyl)x1,2,3,6,7,11b-hexa-
hydro-4H-pyrazino[2,1-a]isoquinoline-4-one] is a
bitter-tastingwhite crystalline powder. It is normally
stable, practically insoluble in water and soluble
in some organic solvents. It is usually a racemate
mixture composed of equal parts of ‘ laevo’ and
‘dextro’ isomers, of which only the former is
schistosomicidally active either in vivo or in vitro.
The metabolism and pharmacodynamics of PZQ
have been reviewed elsewhere (Cioli, Pica-Mattoccia
and Archer, 1995; Cioli and Pica-Mattoccia, 2003;
Doenhoﬀ and Pica-Mattoccia, 2006).
Tablets of PZQ usually contain 600 mg of active
ingredient. Over 30 samples of PZQ tablets from
diﬀerent producers, collected at local user-level in
diﬀerent countries, were tested for quality and both
the original brand and generic products complied
well with international standards (Appleton and
Mbaye, 2001). However, two samples from one
‘manufacturer’ were counterfeit and did not contain
any active ingredient (Sulaiman et al. 2001). A more
recent analysis using 1H nuclear magnetic resonance
(NMR) spectroscopy and multivariate data analysis
(Li et al. 2007) has conﬁrmed that a high-quality
in diﬀerent batches of drug is being maintained.
A syrup formulation containing 600 mg/5 ml suit-
able for small children is available from some manu-
facturers : e.g. Epiquantel, which is produced in
Egypt.
PZQ can now be purchased for US$ 0.10/tablet or
less, and hence the treatment of a school-aged child
or an adult now costs between US$ 0.20 and US$
0.30 (Fenwick et al. 2003; Doenhoﬀ et al. 2008).
However, the price of the drug, availability and
delivery costs can vary from country to country.
Calculations of the amounts of drug to be adminis-
tered have been facilitated by use of a modiﬁed ‘dose
pole ’ tomeasure patients’ heights, thereby negating a
requirement for relatively expensive weighing scales
(Montresor et al. 2005).
Administration of PZQ can result in some side
eﬀects which are nevertheless generally mild and
transient, and available evidence has indicated that
PZQ is a safe drug (Montero and Ostrosky, 1997).
It is of interest that patients treated with laevo-
praziquantel at half the dose of the racemate mixture
had the same cure rates, but suﬀered fewer side ef-
fects (Wu et al. 1991). Of further interest, the bitter
taste of praziquantel which renders it quite unpal-
atable has recently been attributed mainly to the
inactive isomer (Meyer et al. 2009). Moves toward
replacement of the racemic mixture with pure active
isomer are therefore predicated on the basis of both
reducing side eﬀects and improving palatability.
A review of safety data by a committee fromWHO
resulted in a recommendation that PZQ can be
considered for use in pregnant and lactating women
(Allen et al. 2002), but whether or not treatment
of pre-school children should be included in
schistosomiasis control programmes remains an un-
resolved question (Johansen et al. 2007; Stothard
and Gabrielli, 2007a, b).
The eﬃcacy of PZQ is most often measured as a
reduction in schistosome egg excretion rates, and the
result expressed in terms of either a cure rate (the
number of patients who are not excreting schisto-
some eggs after treatment as a percentage of the
number found excreting eggs before drug adminis-
tration) and/or the percentage reduction in the mean
number of eggs excreted by the treated group. Cure
rates of 60% or greater, and sometimes 85–90% are
generally achieved, but complete cures (100%) have
seldom, if ever, been recorded in endemic areas.
Treatment failures are of course a factor pertinent to
the possible evolution of drug-resistance.
Schistosomes have a bi-phasic sensitivity to PZQ
and some other schistosomicidal drugs (Sabah et al.
1986) whereby early migrating larval stages are
susceptible, but susceptibility then decreases to low
levels in 3- to 4-week-old infections and is only
gradually regained as worms mature. Experiments
on laboratory-maintained isolates indicated that
S. mansoni infections become fully susceptible to
PZQ when they are about 6 to 7 weeks old.
A relative lack of eﬃcacy of PZQ against juvenile
schistosome worms in vivo and in vitro (Pica-
Mattoccia and Cioli, 2004) is a potentially signiﬁcant
deﬁciency in the pharmacological proﬁle of this drug
and may help explain poor cure rates and treatment
failures in some studies, particularly in areas with
high rates of transmission. Administration of two
courses of PZQ was advocated for such situations
(Renganathan and Cioli, 1998) and this has resulted
in higher cumulative cure rates (Picquet et al. 1998;
Utzinger et al. 2000a ; N’Goran et al. 2003; Sacko
et al. see in this special issue).
MODE OF ACTION OF PZQ
Some eﬀects of PZQ on schistosome worm mor-
phology and physiology are well-known, but the
detailed molecular mechanisms of drug action are
still poorly deﬁned. Recent work indicates the beta
(b) subunits of voltage-gated calcium ions (Ca2+)
channels are the molecular targets of PZQ (Jeziorski
and Greenberg, 2006). The S. mansoni SmCa(v)bA
and S. japonicum SjCa(v)bmolecules have structural
motifs that diﬀer from those found in other known
b subunits of voltage-gated Ca2+ channels, and
co-expression of these with a mammalian alpha (a)
subunit confers sensitivity of the latter to PZQ. The
b interaction domains (BIDs) of SmbA and Sjb lack
two conserved serines, each of which constitutes a
consensus site for protein kinase C phosphorylation
and it is the absence of these serines that appears
to render schistosome cells sensitive to PZQ (Kohn
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et al. 2003a, b). The topic has been reviewed
moreextensivelyelsewhere (Jeziorski andGreenberg,
2006).
Cytochalasin D abolishes the schistosomicidal
activity of PZQ (Pica-Mattoccia et al. 2007b), but –
contrary to expectations – Ca2+ inﬂux into PZQ-
exposed schistosomes was not blocked. Rather, adult
worms pre-treated with cytochalasin D and im-
mature (drug-refractory) schistosomes survived well
after a large Ca2+ uptake induced by PZQ (Pica-
Mattoccia et al. 2008). The results with cytochalasin
D raise doubts whether Ca2+ inﬂux is crucial in
the antischistosomal activity of PZQ and perhaps
therefore also about the relevance of schistosome
Ca2+ channels.
PZQ would perhaps be expected to bind to its
molecular target(s). However, attempts to identify
likely receptors by aﬃnity chromatography were
unsuccessful (Troiani et al. 2007) and an earlier re-
port that PZQ binds adult S. mansoni actin (Tallima
and El Ridi, 2007) was therefore not conﬁrmed.
Damage caused by PZQ increases exposure of
antigens on the worm surface, particularly over male
worm tubercles (Harnett andKusel, 1986) and this in
turn seemingly renders the worms more susceptible
to antibody attack. This drug-induced antigen ex-
posure is assumed to account for the synergistic eﬀect
between PZQ and host antibodies in killing worms
in vivo (Doenhoﬀ et al. 1987).
RESISTANCE TO PZQ IN S. MANSONI
There is currently much debate whether PZQ is
destined to become less useful because of the
potential emergence of drug resistance. There are
several strands of evidence that this could indeed
occur. Thus, when PZQ was used in an attempt to
control an outbreak of intestinal schistosomiasis that
had reached epidemic proportions in northern
Senegal (Southgate, 1997) the treatment gave cure
rates of only 18–39% (Stelma et al. 1995). These were
alarmingly low comparedwith the normally expected
60–90% and increasing the dose gave no signiﬁcant
improvement (Guisse et al. 1997; TchuemTchuente
et al. 2001). Two further observations indicated that
the response of S. mansoni in northern Senegal to
PZQwas aberrant: (1) a parasite line derived from an
isolate from that area was less susceptible to PZQ
than other isolates used as controls (Fallon et al.
1997) ; (2) in this area oxamniquine given as a routine
dose of 20 mg/kg gave a cure rate of 79%, compared
with 36% in a simultaneously-treated control group
given 40 mg/kg PZQ (Stelma et al. 1997).
Secondly, during the period of extensive use of
PZQ in Egypt, Ismail and colleagues (1996) treated
1607 S. mansoni-infected patients in the Nile delta
region with PZQ at 40 mg/kg and after an additional
two treatments, the last at 60 mg/kg, 1.6% of the
patients were still passing viable eggs. Several
isolates were established in laboratory-maintained
life cycles from eggs passed by uncured patients, and
adult worms of these isolates were found to have PZQ
ED50s 2- to 5-fold greater after PZQ treatment in
mice than isolates that had been established from
eggs passed before treatment by patients who had
been cured (Ismail et al. 1996).
Finally, it has been shown that resistance to PZQ
could be selected for in a laboratory-maintained
S. mansoni isolate by applying drug pressure to
successive mouse passages (Fallon and Doenhoﬀ,
1994). Collaborative experiments performed in lab-
oratories in Italy, Egypt and the UK, using stan-
dardized protocols to estimate the ED50s of the
above-mentioned and other S. mansoni isolates that
were putatively either resistant or sensitive to PZQ,
conﬁrmed that diﬀerent isolates of this species do
have varied sensitivities to PZQ (Cioli et al. 2004).
A further study was designed to investigate the
mode of inheritance of the partial insensitivity ex-
hibited by the drug-selected schistosomes. Single
male and single female worms of the two strains,
assorted in the four possible combinations, were in-
troduced into the mesenteric veins of mice and eggs
produced by each pair were used as the source of F1
progeny. PZQ sensitivity of the latter was assessed
using both in vivo and in vitro methods and the re-
sults from both approaches lead to the conclusion
that hybrid schistosomes of the F1 generation have a
drug sensitivity intermediate between those of the
two parental strains. This outcome is thus suggestive
of a pattern of partial dominance for the trait under
study (Pica-Mattoccia et al. 2009).
In the absence of ﬁrm knowledge about the
mechanism of action of PZQ, hypotheses about
mechanisms of resistance to this drug are inevitably
speculative. After the discovery that the amino acid
sequence of b subunits of voltage-gated Ca2+ chan-
nels may account for schistosome sensitivity to
PZQ the sequences of these molecules in several
PZQ-resistant and -sensitive isolates were compared.
However, no meaningful diﬀerences were found in
the sequences or rates of expression of cDNAs of
either SmCavb1 or SmCavb2 that would account for
diﬀerences in PZQ sensitivity between isolates (Valle
et al. 2003). These observations do not disprove the
hypothesis that Ca2+ channels are involved in PZQ
activity, since factors other than modiﬁcation of the
drug target, such as changes in mechanisms of drug
uptake and/or eﬄux may account for insusceptibility
to the drug. It is also important to note that in
all the above-mentioned studies only relatively few
schistosome isolates have been studied.
In any current discussion on drug resistance a
confounding factor is that immature schistosome
worms are insensitive to the most commonly used
schistosomicidal chemotherapy. It is therefore ar-
gued that low cure rates and observed treatment
failures are due to the presence of immature worms in
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the patients at the time they are treated (Renganathan
and Cioli, 1998; Gryseels et al. 2001), an argument
supported by the higher cumulative cure rates that
are achieved when two treatments are given a few
weeks apart (Picquet et al. 1998; Utzinger et al.
2000a ; N’Goran et al. 2003, Sacko et al. see in this
special issue). Nevertheless, a meta-analysis com-
paring the data from Senegal with those from other
areas indicated that when intensity of infection
and sensitivity of diagnosis had been accounted for,
Senegal was atypical in showing cure rates signiﬁ-
cantly lower than expected. It was concluded there-
fore that ‘‘…..the suspicion of tolerance or resistance
to PZQ… cannot be ruled out’’ (Danso-Appiah and
de Vlas, 2002).
A collaborative study has recently been under-
taken to test the PZQ-sensitivity of African S. man-
soni isolates as soon as possible after they were
collected from their endemic areas and brought into
laboratory-maintained life cycles. The results (un-
published) are consistent with the conclusion of the
earlier collaborative study (Cioli et al. 2004) that
S. mansoni isolates diﬀer in their sensitivity to PZQ.
THE ROLE OF ‘ REFUGIA ’ IN DRUG-RESISTANCE
‘Refugium’ is an ecological term for the location of
an isolated or relict population of a once widespread
animal or plant species. The concept has been
adapted in consideration of the factors inﬂuencing
evolution of drug-resistant helminths, particularly
those of veterinary importance (vanWyk, 2001). It is
hypothesized that if helminth populations in refugia
remain large relative to the number of incoming
oﬀspring of drug-treated, but uncured (and thus
putatively drug-resistant) parasites, the impact of the
latter on the genetic constitution of the population as
a whole will be small.
Schistosome refugia will be found in human
populations with high infection prevalences and in-
tensities, subjected to chemotherapy only randomly,
selectively and/or intermittently, and also in infested
environments in which intense transmission is oc-
curring without interference from measures inten-
ded to control it (e.g. mollusciciding). The extent of
refugia is however likely to decline during the course
of control programmes built around large-scale ap-
plication of PZQ (Hagan et al. 2004; Doenhoﬀ et al.
2008).
ALTERNATIVES TO PZQ
PZQ is not a perfect drug – viz. the relatively poor
cure rates it has given in some areas of Africa (Stelma
et al. 1995; Kabatereine et al. 2003), which may in
turn be partly due to its lack of eﬀectiveness against
immatureschistosomes.Furthermore,althoughthere
is as yet no sign of PZQ-resistance evolving, it would
be unwise to assume that this will never happen. The
position of PZQ as the only drug for mass treatment
in current African control programmes and the
likelihood that it seldom achieves 100% cure rates
make it vulnerable (Doenhoﬀ, 1998). Cure rates
based on egg counts are in any case usually over-
estimates because of the inherent insensitivity of egg
counting methods routinely used in endemic areas.
Thus, for example, Kato-Katz thick smear exam-
inations performed on only one day indicated higher
cure rates when compared with those done over
several days (Utzinger et al. 2000a ; Botros and
Bennett, 2007).
Alternative or additional drugs are therefore
needed urgently, but unfortunately there are rela-
tively few options.
Oxamniquine
Oxamniquine is eﬀective only against S. mansoni.
It is ineﬀective against S. haematobium, S. japonicum
or other schistosome species. In contrast to PZQ, the
mechanism of action of oxamniquine is relatively
well understood: it has to be activated by a parasite
sulfotransferase and resistant/insusceptible schisto-
somes lack the enzymatic activity (Pica-Mattoccia
et al. 2006).
Also in contrast to PZQ, the price of oxamniquine
has remained high and for this reason alone it is
unlikely to be used much in Africa: so far its use has
been almost entirely restricted to Brazil and other
South American countries. Its use was, however,
quite extensive: over 12 million doses were admin-
istered in Brazil in a schistosomiasis control pro-
gramme organized by that country’s Ministry of
Health (Katz and Coelho, 2008).
Oxamniquine may be particularly prone to the
problem of drug-resistance (Coles et al. 1987), but
it may be needed because it is eﬀective against
S. mansoni infections in an area in which PZQ gave
poor cure rates (Stelma et al. 1997).
Artemisinin and its derivatives
Artemisinin, the active ingredient of the plant
Artemisia annua, is a sesquiterpene lactone from
which semi-synthetic derivatives have been synthe-
sized, including artemether and artesunate. These
are potent anti-malaria drugs and millions of doses
have been administered for this purpose. Artemi-
sinin activity against S. japonicum was discovered
in the early 1980s and in vivo activity against
other schistosome species conﬁrmed subsequently
(Utzinger et al. 2007). These compounds are well-
tolerated and give no or only mild side eﬀects, but
their mechanisms of action are not yet fully under-
stood.
Artemisinins are of particular interest because, in
contrast to PZQ and oxamniquine, they show highest
activity against immature worms. Artemether and
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artesunate have therefore been used in China as
‘prophylactics ’ againstS. japonicum infection during
major ﬂoods and their chemoprophylactic eﬀective-
ness has also been demonstrated in Africa against
both S. mansoni (Utzinger et al. 2000b) and S. hae-
matobium (N’Goran et al. 2003). They may be par-
ticularly useful in areas with high rates of infection
transmission and where PZQ is less eﬀective,
perhaps because of the insensitivity of immature
schistosomes to the latter.
Proposals for use of artemisinins in areas where
Plasmodium spp. and schistosomes co-exist, as is the
case in many areas of sub-Saharan Africa, will nat-
urally raise concerns about the generation of drug-
resistance in the former. Areas where malaria and
schistosomiasis co-exist could however be found
to allow the eﬀects of the artemisinins, particularly
artemisinin-based combination therapies (ACTs)
being used against malaria, to be assessed and moni-
tored for their eﬀects on schistosomiasis (Keiser and
Utzinger, 2007; Utzinger et al. 2007).
Other compounds with potential schistosomicidal
activity
A lack of ﬁnance is always likely to restrain the
search for completely new drugs against so-called
neglected tropical diseases such as schistosomiasis,
but there may be some interest in resurrecting
compounds that showed promise before PZQ over-
took the market. One of these is Ro 15-5458, namely
[10-(2-diethylamino) ethyl-9-acridanone(thiazolidin-
2-ylidene) hydrazone], which has shown activity
against S. mansoni in non-human primates at rela-
tively low doses (Sturrock et al. 1987; Sulaiman et al.
2001). If the toxicity of Ro 15-5458 is acceptable and
if manufacturing costs are cheap enough, it could
provide a useful alternative to PZQ.
The anticonvulsant clonazepam and its methyl
derivative, designated Ro 11-3128, cured S. mansoni
and S. haematobium in mice and hamsters, though
S. japonicum was completely refractory to them.
Importantly, the drug was active against immature
stages and initial toxicology and mutagenicity trials
proved that the drug was well tolerated in animals
(Stohler, 1978). A clinical study in South Africa
showed that a dose of 0.2–0.3 mg/kg was curative for
most patients infected with either S. mansoni or
S. haematobium (Baard et al. 1979), but, the drug
unfortunately caused a severe and long lasting sed-
ation, accompanied by ataxia and muscle relaxation
(O’Boyle, Lambe and Darragh, 1985). Further de-
velopment of the drug was abandoned because of
these adverse events. Although PZQ and Ro 11-3128
do not share the same binding sites in the parasite
(Pica-Mattoccia et al. 2007a), the two drugs other-
wise have some intriguing similarities.
A novel line of potential schistosomicides has been
identiﬁed based on a distinction between host and
parasite physiology with respect to detoxiﬁcation of
reactive oxygen species. Thus, mammals have two
distinct detoxiﬁcation enzymes, thioredoxin reduc-
tase and glutathione reductase, but in schistosomes
one molecule, thioredoxin-glutathione reductase,
performs both these catalytic activities (Kuntz et al.
2007). Phosphinic amides and oxadiazoles have been
identiﬁed as inhibitors of the schistosome enzyme
by high-throughput screening and 4-phenyl-1,2,5-
oxadiazole-3-carbonitrile-2-oxide was schistosomi-
cidal in vivo (Cioli et al. 2008; Simeonov et al. 2008).
Analagously to the artemisinins, 1,2,4-trioxolanes
(OZ) have for the most part been assessed primarily
as antimalarials, though one of the series (OZ78) has
shown good activity both in vitro and in vivo against
juvenile and adult stages of S. mansoni and S. japo-
nicum (Xiao et al. 2007). The antimalarial meﬂoquine
appears also to have schistosomicidal activities (Van
Nassauw et al. 2008; Keiser et al. 2009).
Finally, other schistosome-speciﬁc enzymes, such
as cysteine proteases (Abdulla et al. 2007), may also
be good targets for development of novel drugs.
Myrrh and triclabendazole
There have been reports that myrrh, the resinous
dried sap of the plant Commiphora myrrha, has
schistosomicidal activity in experimental animals
(Badria et al. 2001) and humans (Sheir et al. 2001).
Independent evaluations of myrrh in experimental
animals (Botros et al. 2004) and humans (Barakat,
Elmorshedy and Fenwick, 2005; Botros et al.
2005c) have however found very little evidence for
such activity and this product should therefore be
removed from the market for schistosomicides.
Recently, the in vivo eﬃcacy of triclabendazole and
its major metabolites has been investigated in dif-
ferent strains ofS. mansoni. Unfortunately, only very
low and inconsistent worm burden reductions have
been found, and hence it was concluded that tricla-
bendazole is also unlikely to hold promise for further
development as an antischistosomal drug (Keiser
et al. 2006; Barduagni et al. 2008).
CONCLUSIONS AND SOME SUGGESTIONS
FOR FUTURE WORK
Control of schistosomiasis in sub-Saharan Africa will
be based on the use of PZQ for the foreseeable future.
With so few alternative drugs available it is impera-
tive that eﬀorts are made to ensure that PZQ retains
its usefulness for as long as possible.
Mechanisms of action of PZQ and markers
of resistance
Elucidation of the mechanisms of action of PZQ is
needed urgently, particularly with regard to identi-
ﬁcation of its molecular target(s) in the parasite. Such
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knowledge could allow potential genetic markers of
resistance to be sought and veriﬁed and analogues to
be synthesized and tested.
With regard to drug-resistance markers, two in-
dependent studies have been published so far. In
one study, two major DNA nucleotide sequence
diﬀerences were found between an Egyptian PZQ-
resistant isolate and several PZQ-sensitive isolates
from the same endemic area (Tsai et al. 2000). In
the second study, subtractive PCR showed a PZQ-
sensitive and a PZQ-resistant isolate to be diﬀerent
in the expression and activity of the mitochondrial
enzyme cytochrome C-oxidase (Pereira et al. 1998).
Surprisingly, neither of these possible resistance
markers has been investigated further.
Work to investigate whether the schistosomicidal
activity of PZQ is immune-dependent in humans is
warranted, and if shown to be so, identiﬁcation of the
antigens putatively implicated in the phenomenon
could prove useful. One study along these lines
showed that cure rates in HIV-positive subjects were
as high as in HIV-negatives (Karanja et al. 1998;
Mwanakasale et al. 2003), but the reason for this
‘negative’ result may be that despite the viral infec-
tion the former already had the synergistically-active
immune eﬀector mechanisms in place.
A need for more work on freshly-collected isolates
The results of a recent project to investigate the
sensitivity of newly-collected African S. mansoni
isolates to PZQ indicated that they varied markedly
from each other in this respect (D. Cioli et al. unpub-
lished observations). An earlier study also showed
that new S. mansoni isolates (from Brazil) diﬀered
in their drug-sensitivities and that the diﬀerences
were not necessarily related to whether or not they
had been derived from a treatment failure (Araujo
et al. 1980). Recently collected isolates from Egypt,
even though retrieved from patients responding
to treatment, were relatively insusceptible to PZQ
when tested in mice (S. Botros et al. unpublished
observations).
Passage of S. mansoni through murine hosts
in particular is known to exert a strong selection
pressure (Coles, 1971; LoVerde et al. 1985) and it
therefore seems preferable that collection of evidence
about PZQ-sensitivity ofS. mansoni isolates in future
be restricted to freshly-collected isolates. Implicit in
this recommendation is a need for guidelines for the
collection and examination of samples that will yield
representative results, though the formulations of
these guidelines will themselves evolve as evidence
from new isolates accumulates.
It will of course not be possible to pursue all
avenues of research on new isolates immediately after
they have been collected. Archiving of genetic ma-
terial from representative isolates as early as possible
after removal from the ﬁeld is therefore to be
recommended and how and why schistosome isolates
(may) change their characteristics during laboratory
maintenance need to be investigated.
Procedures for monitoring changes in drug sensi-
tivity that may be induced during the course of
PZQ-based control programmes also need to be
formulated and put into action, but it is likely that
this will only be possible after baselines have been
established as a result of examination of a satisfac-
torily large and representative set of new isolates.
Estimates of biological ﬁtness of putatively-
resistant parasites will be needed in order to calculate
their potential impact. Some comparisons have
already been made on isolates known to vary in their
sensitivity to PZQ (Liang et al. 2001; William et al.
2001), but these results have to be interpreted with
caution because although in the latter study each
isolate had been collected from a patient with treat-
ment failure, the parasites were not examined while
growing in their natural intermediate or deﬁnitive
hosts. More appropriate experimental designs are
needed, but unfortunately the constraint with regard
to the natural deﬁnitive host, i.e. humans, is in-
superable. It would seem appropriate for laboratories
in endemic areas to generate the capacity and take
responsibility for implementing the above recom-
mendations.
S. haematobium
More PZQ is likely to be used againstS. haematobium
than S. mansoni, given that infections of the former
are more prevalent and generally more pathogenic in
countries south of the Sahara (van der Werf et al.
2003). Evidence from in vitro cultures suggests that
S. haematobium is marginally more sensitive to PZQ
than S. mansoni (Botros et al. 2005a, 2008). There
are, however some case reports of S. haematobium
infections failing to respond to treatment with PZQ
(da Silva et al. 2005; Alonso et al. 2006).
As for S. mansoni, there is fortunately no evidence
yet that S. haematobium is developing resistance to
PZQ, but nearly all our knowledge about the eﬀects
of PZQ on African schistosomes is derived from
work on S. mansoni for the expedient reason that
laboratory-maintained life-cycles of S. haematobium
are more diﬃcult to maintain in rodents. As far as we
know no new life cycles of this species have been
established for experimental purposes in the recent
past and remedies for this deﬁciency are urgently
needed.
Estimating the impact of incomplete cures
The usual way to select for drug resistance is to ad-
minister chemotherapy that does not result in com-
plete cure. It is unlikely that any S. mansoni-infected
population mass-treated with PZQ has been com-
pletely cured and most recorded cure rates based on
M. J. Doenhoﬀ and others 1830
egg detection are likely to be over-estimates because
of the insensitivity of the egg detection methods
(Doenhoﬀ, 1998; Utzinger et al. 2001; Booth et al.
2003; Botros and Bennett, 2007).
The eﬃcacy of treatment will need continuous
monitoring and attention should be given to what is
being measured. In one of the few follow-up studies
carried out so far no apparent increase in treatment
failures was found in Egyptian villages subjected to
repeated chemotherapy with PZQ for over a decade
(Botros et al. 2005b). This result should, however be
tempered by the realization that rates of reduction in
egg counts were generally lower than those achieved
in this area early in the treatment programme, and
that the reduction in geometric egg count in the
group aged <20 years in this particular study was
only 2.8% (Botros et al. 2005b).
Treatment of infants
For epidemiological reasons, as well as convenience,
current treatment programmes tend to be con-
centrated on schoolchildren and they are thereby
likely to discount the possibly signiﬁcant contri-
bution to transmission of infection by infants and
preschool-aged children (Stothard and Gabrielli,
2007a). There is some evidence that cure rates tend
to be lower in children than in adults (Kabatereine
et al. 2003) and it would be of interest to determine
whether this discrepancy is attributable to the
schistosomicidal action of PZQ being in part immune
(antibody)-dependent and thus due to children
having less developed immunity than adults.
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